Drug Trial Radar · NCT03067441
Assessment of the Long-Term Safety and Efficacy of Bempedoic Acid (CLEAR Harmony OLE)
Last checked: Nov 20, 2026Latest source record: Mar 1, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,462
Actual
Start
Feb 3, 2017
Primary completion
Nov 5, 2019
Study completion Nov 5, 2019
Sponsor
- Lead sponsor
- Esperion Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Mar 1, 2017
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to see if bempedoic acid (ETC-1002) is safe and well-tolerated in patients with high cardiovascular risk and elevated LDL cholesterol that is not adequately controlled by their current therapy.
Conditions
- Hypercholesterolemia
- Atherosclerotic Cardiovascular Disease
Interventions
bempedoic acidDrug
bempedoic acid 180 mg tablets taken orally, once per day.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Treatment-Emergent Adverse Events (TEAEs)Time frame: Up to Week 82
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Jedidiah Clinical Research
Tampa, Florida
L-MARC Research Center
Louisville, Kentucky
Sentral Clinical Research Services
Cincinnati, Ohio
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.